Bard E-Luminexx
This article was originally published in The Gray Sheet
Executive Summary
Self-expanding nitinol stent receives FDA market go-ahead to treat common or external iliac artery occlusive disease, the firm announces Dec. 8. A 134-patient, multi-center, non-randomized trial of E-Luminexx versus objective performance criteria showed nine-month primary patency of 94.03% and a site-reported anatomic success rate (<30% final residual stenosis) of 98.72%